What Is Tesamorelin?
Tesamorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to release growth hormone.
It's FDA-approved (brand name Egrifta) for one specific use: reducing excess abdominal fat in people with HIV who have lipodystrophy—a condition where fat builds up around the abdomen, often related to HIV treatment.
How Well Does It Work in People With HIV?
In clinical trials, tesamorelin significantly reduced visceral fat (the deep belly fat around organs) in people with HIV-associated lipodystrophy—by roughly 15–20% over six months on average. Studies also suggest it may reduce liver fat in this population.
What About People Without HIV?
This is where evidence becomes limited:
- Tesamorelin is not FDA-approved for belly fat in people without HIV
- A small number of studies have explored it in other groups, such as people with abdominal obesity, with some showing reductions in visceral fat
- There are no large trials establishing its benefits or long-term safety in the general population
Because visceral fat responds to growth hormone, it's plausible tesamorelin could have similar effects in people without HIV—but it hasn't been proven at scale.
Side Effects and Safety
- Joint pain and muscle aches
- Swelling or fluid retention
- Injection site reactions
- Increased blood sugar and risk of diabetes
- Numbness or tingling
- Fat tends to return after stopping
It's not recommended for people with active cancer, and IGF-1 and blood sugar should be monitored.
Proven Ways to Reduce Belly Fat
- Regular aerobic exercise and strength training
- Weight loss through nutrition changes
- Limiting alcohol and added sugars
- Improving sleep and managing stress
- GLP-1 medications, which significantly reduce visceral fat
Learn more about provider-guided weight loss here: Heva Weight Loss
The Bottom Line
Tesamorelin is proven to reduce belly fat in people with HIV-associated lipodystrophy. Evidence for people without HIV is limited, and it's not approved for that use, so proven approaches remain the first choice.